Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs-Reference-Cited by-同舟云学术

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Published:2015-06-18 Issue:25 Volume:125 Page:3905-3916
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ninomiya Soranobu¹,Narala Neeharika¹,Huye Leslie¹,Yagyu Shigeki¹,Savoldo Barbara¹²,Dotti Gianpietro¹³,Heslop Helen E.¹²³,Brenner Malcolm K.¹²³,Rooney Cliona M.¹²⁴,Ramos Carlos A.¹³

Affiliation:

1. Center for Cell and Gene Therapy, Houston Methodist Hospital, Texas Children’s Hospital, and Baylor College of Medicine, Houston, TX; and

2. Departments of Pediatrics,

3. Medicine, and

4. Pathology and Immunology, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX

Abstract

Key Points Tumor IDO inhibits CD19-CART activity, likely via induction of the kynurenine pathway, whose metabolites directly inhibit T cells. Fludarabine and cyclophosphamide, frequently used before CART administration, downregulate IDO expression in lymphoma cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/25/3905/1386305/3905.pdf

Reference43 articles.

1. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.;Cruz;Blood,2013

2. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.;Porter;N Engl J Med,2011

3. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.;Kalos;Sci Transl Med,2011

4. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.;Kochenderfer;Blood,2013

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

2. The effectiveness of ruxolitinib and cyclophosphamide combination on T helper 17 and regulatory T cells in rat experimental membranous glomerulonephritis;Molecular and Cellular Probes;2024-08

3. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination;Cancer Letters;2024-08

4. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours;Expert Review of Clinical Immunology;2024-07-17

5. CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors;Med;2024-06